Concentration controlled and concentration defined clinical trials: Do they offer any advantages for antimicrobial chemotherapy?

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 1, 1996, Pages 1-5

  Macgowan, Alasdair ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

CLINICAL TRIAL; DRUG MONITORING; EDITORIAL; HUMAN; MINIMUM INHIBITORY CONCENTRATION;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFECTION;

EID: 0029898046     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.1     Document Type: Editorial

References (41)

1. Bauernfeind, A. (1993). Questioning dosing regimens of ciprofloxacin Journal of Antimicrobial Chemotherapy 31, 789-98.
2. Blaser, J., König, C., Simmen, H.-P. & Thurnheer, U. (1994). Monitoring serum concentrations for once-daily netilmicin dosing regimes. Journal of Antimicrobial Chemotherapy 33, 341-8.
3. Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance Antimicrobial Agents and Chemotherapy 31, 1054-60.
4. Carbon, C. & Cefpirome Study Group. (1992). Prospective randomised phase II study of intravenous cefpirome 1 g or 2 g bd in the treatment of hospitalised patients with different infections. Journal of Antimicrobial Chemotherapy 29, Suppl. A, 87-94.
5. Cowling, P., Case, C. P., MacGowan, A. P., Lovering, A. M , Humphreys, H., Reeves, D S. et al. (1992). Cefuroxine axetil in sick elderly patients. Journal of Antimicrobial Chemotherapy 29, 350-1.
6. Cowling, P., Rogers, S., McMullin, C. M., White, L. O , Levering, A. M., MacGowan, A. P. et al. (1991). The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. Journal of Antimicrobial Chemotherapy 28, 101-7.
7. Cronberg, S. (1994). Simplified monitoring of aminoglycosides. Journal of Antimicrobial Chemotherapy 34, 819-27.
8. Drusano, G. L., Johnson, D. E., Rosen, M. & Standiford, H. C. (1993). Pharmacodynamic of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Psuedomonas sepsis. Antimicrobial Agents and Chemotherapy 37, 483-90.
9. Edwards, J. R. (1991). The pre-clinical evaluation of meropenem, a new paraenteval carbapenem. In Proceedings of the Fifth International Symposium on Clinical and Environmental Microbiology, Brescia, 1991. pp. 190-202. Brixia Academic Press.
10. Flexner, C., van der Horst, C., Jacobson, M. A., Powderly, W., Duncanson, F., Ganes, D. et al. (1994). Relationship between plasma concentrations of 3′-deoxy-3′fluorothymidine (alovudine) and antinetroviral activity in two concentration-controlled trials. Journal of Infectious Diseases 170, 1394-403.
11. Forrest, A., Ballow, C. H., Nix, D. E., Birmingham, M. C. & Schentag, J. J. (1993a). Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy 37, 1065-72.
12. Forrest, A., Nix, D E., Ballow, C. H., Goss, T. F., Birmingham, M. C & Schentag, J. J. (1993b). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
13. Freeman, C. D , Quintiliam, R. & Nightingale, C H. (1993). Vancomycin therapeutic drug monitoring: is it necessary? Annals of Pharmacology 27, 594-8.
14. Gilbert, D. N. (1991). Once-daily aminoglycoside therapy Antimicrobial Agents and Chemotherapy 35, 399-405.
15. Gould, I. M., Milne, K. & Jason, C. (1990). Concentration-dependent bacterial killing, adaptive resistance and post antibiotic effect of ciprofloxacin alone and in combination with gentamicin. Drugs Under Experimental and Clinical Research 16, 621-8.
16. Johnson, E. J., MacGowan, A. P., Potter, M. N., Stockley, R. J., White, L. O., Slade, R. R. et al (1990) Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy Journal of Antimicrobial Chemotherapy 25, 837-42.
17. Kelsey, M C. (1987). A review of the pharmacokinetics and side effects of cefuroxime axetil. In The Management of Lower Respiratory Tract Infections with Cefuroxime Axetil (Emmerson, A. M., Ed), pp. 25-33 Royal Society of Medicine Services International Congress and Symposium Series, no. 124. Royal School of Medicine, London.
18. Kemper, P. & Kohler, D. (1992). A double-blind study of two dosage regimens of lomefloxacin in bacteriogically proven exacerbation's of chronic bronchitis of Gram-negative ethology. American Journal of Medicine 92, Suppl. 4A, 98-102.
19. Körner, R. J., Nicol, A., Reeves, D. S., MacGowan, A. P. & Hows, J. (1994). Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. Journal of Infection 29, 73-6.
20. Kovarik, J. M., Hoepelman, I. M. & Verhoef, J. (1989). Once-daily aminoglycoside administration: new strategies for an old drug. European Journal of Clinical Microbiology and Infectious Diseases 8, 761-9.
21. Levy, G. (1993). Concentration-controlled versus concentration-defined clinical trials. Clinical Pharmacology and Therapeutics 53, 385-8.
22. Levy, G., Ebling, W. F. & Forrest, A. (1994). Concentration or effect controlled clinical trials with spare data. Clinical Pharmacology and Therapeutics 56, 1-8.
23. Leiberman, R. & Nelson, R. (1993). Dose-response and concentration-response relationships: clinical and regulatory perspectives. Therapeutic Drug Monitoring 15, 498-502.
24. Lønning, P. E. (1993). Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics 25, 1-5.
25. Lovering, A. M., Vickery, C. J., Watkins, S., Leaper, D., McMullin, C. M., Reeves, D. S. et al. (1995). The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. Journal of Antimicrobial Chemotherapy 36, 165-72.
26. MacGowan, A. P. (1994). Once daily aminoglycosides therapy: serum monitoring and clinical indications. Syva Drug Monitor 1, 1-6.
27. MacGowan, A. P., McMullin, C. M., White, L. O., Reeves, D. S., Davis, E. & Speller, D. C. E. (1992). Serum monitoring of teicoplanin. Journal of Antimicrobial Chemotherapy 30, 399-402.
28. MacGowan, A. P. & Reeves, D. S. (1994). Serum aminoglycoside concentrations: the case for routine monitoring. Journal of Antimicrobial Chemotherapy 34, 829-37.
29. Maggiolo, F., Taras, A., Frontespezi, S., Bottari, F., Legnani, M C & Suter, F. (1993). Bactericidal activity of two different dosage regimens of inpenem in an in-vitro dynamic model. Journal of Antimicrobial Chemotherapy 32, 295-300.
30. Moore, R. D., Leitman, P. S. & Smith, C. R. (1987). Clinical response to aminoglycoside therapy: importance of ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155, 93-9.
31. Peck, C. C. (1993). Concentration-controlled versus concentration-defined clinical trials-reply. Clinical Pharmacology and Therapeutics 53, 385-7.
32. Pryka, R. D. & Haig, G. M. (1994) Meropenem: a new carbapenem antimicrobial. Annals of Pharmacotherapy 28, 1045-54.
33. Reeves, D. S., MacGowan, A. P., Holt, H. A., Lovering, A. M., Warnock, D. W. & White, L. O. (1995) Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK. NEQAS for antibiotic assays for participants October 1993. Journal of Antimicrobial Chemotherapy 35, 213-26.
34. Rex, J. H., Bennett, J. E , Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E. et al. (1994). A randomised trial comparing fluconazole with amphoteracin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 331, 1325-30.
35. Rizk, E. (1992). A world-wide clinical overview of lomefloxacin, once daily fluoroquinolone International Journal of Antimicrobial Agents 2, 67-78.
36. Sanathanan, L. P. & Peck, C. C. (1991). The randomised concentration-controlled trial an evaluation of its sample size efficiency. Controlled Clinical Trials 12, 780-94.
37. Sanathanan, L. P., Peck, C. C., Temple, R., Lieberman, R. & Pledger, G. (1991). Randomisation, PK-controlled dosing, and titration: an integrated approach for designing clinical trials. Drug Information Journal 25, 425-31.
38. Saunders, N. J. (1994). Why monitor peak vancomycin concentration? Lancet 344, 1748-50.
39. Shaw, L. M., Bonner, H. S., Fields, L. & Leiberman, R. (1993). The use of concentration measurements of parent drug and metabolites during clinical trials. Therapeutic Drug Monitoring 15, 483-7.
40. Wilson, A. P. R , Grüneberg, R. N. & Neu, H. (1993). Dosage recommendations for teicoplanin. Journal of Antimicrobial Chemotherapy 32, 792-6.
41. Working Party Report of the British Society for Antimicrobial Chemotherapy (1993) Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation. a review and recommendations. Journal of Antimicrobial Chemotherapy 32, 5-21.